Related Experiment Videos
Pharmacokinetics of iopamidol 370 in infants and children during ivp
Insights
This study evaluated iopamidol 370 pharmacokinetics in infants and children with urinary tract infections. Results showed similar pharmacokinetic parameters to adults, suggesting safe use of this nonionic contrast agent.
Area of Science:
- Radiology and Imaging
- Pediatric Pharmacology
- Pharmacokinetics
Background:
- Recurrent urinary tract infections (UTIs) are common in infants and children.
- Iopamidol 370 is a nonionic, water-soluble, organic iodine contrast medium used in medical imaging.
- Understanding the pharmacokinetic profile of contrast agents in pediatric populations is crucial for safe and effective use.
Purpose of the Study:
- To evaluate the pharmacokinetic parameters of iopamidol 370 in infants and children undergoing intravenous pyelography (IVP).
- To compare the pharmacokinetic data in pediatric patients with existing data from adult populations.
Main Methods:
- A cohort of pediatric patients with symptomatic recurrent UTIs was divided into three age groups (0-24, 25-72, 73-120 months).
- Iopamidol 370 was administered intravenously at a dose of 1 ml/kg + 6 ml.
- Blood and urine samples were collected over 24 hours for pharmacokinetic analysis using a bicompartmental open model.
Main Results:
- Key pharmacokinetic parameters were estimated: t1/2 alpha (0.33 h), t1/2 beta (1.92 h), Vc (0.40 L/kg), V beta (0.20 L/kg), and Cl (0.16 L/kg).
- These parameters did not show significant differences when compared to reported values in adult literature.
- No significant variations in pharmacokinetic parameters were observed across the different pediatric age groups studied.
Conclusions:
- The pharmacokinetic profile of iopamidol 370 in infants and children is comparable to that observed in adults.
- These findings support the established safety and efficacy of iopamidol 370 for IVP in pediatric patients.
- Further research could explore specific dosing adjustments or long-term outcomes in diverse pediatric populations.
Abstract:
This research was aimed at evaluating the pharmacokinetic parameters of iopamidol 370 (a nonionic water organic iodine compound) during ivp in infants and children. All children examined in the study had symptomatic recurrent urinary tract infections; they were divided into three groups according to age (0-24 months; 25-72 months; 73-120 months). The contrast medium was injected in a dose of 1 ml/kg + 6 ml. Blood and urine samples were taken at regular time intervals over a 24-hour period in children, whereas in infants only blood samples were collected. Pharmacokinetic parameters were estimated using a bicompartmental open model, as follows: t1/2 alpha (h) = 0.33; t1/2 beta (h) = 1.92; Vc (l/kg) = 0.40; V beta (l/kg) = 0.20; Cl (l/kg) = 0.16. These values were not significantly different, as far as our patients were concerned, from those reported in literature for adults.